Literature DB >> 19928388

Body mass index-independent metabolic alterations in narcolepsy with cataplexy.

Francesca Poli1, Giuseppe Plazzi, Guido Di Dalmazi, Danilo Ribichini, Valentina Vicennati, Fabio Pizza, Emmanuel Mignot, Pasquale Montagna, Renato Pasquali, Uberto Pagotto.   

Abstract

STUDY
OBJECTIVES: To contribute to the anthropometric and metabolic phenotyping of orexin-A-deficient narcoleptic patients, and to explore a possible risk of their developing a metabolic syndrome.
DESIGN: We performed a cross-sectional study comparing metabolic alterations in patients with narcolepsy with cataplexy (NC) and patients with idiopathic hypersomnia without long sleep time.
SETTING: University hospital. PATIENTS: Fourteen patients with narcolepsy with cataplexy and 14 sex and age-matched patients with idiopathic hypersomnia without long sleep time.
INTERVENTIONS: N/A. MEASUREMENTS AND
RESULTS: Metabolic parameters were evaluated by measuring body mass index (BMI), waist circumference (also with abdominal computed tomography), blood pressure, and daily calorie intake (3-day diary). Chronotypes were assessed through the morningness-eveningness questionnaire. Lumbar puncture for cerebrospinal fluid orexin-A determination and HLA typing were performed. Patients with narcolepsy with cataplexy (all HLA DQB1*0602 positive and with cerebrospinal fluid orexin-A levels < 110 pg/mL) had a higher BMI and BMI-independent metabolic alterations, namely waist circumference, high-density lipoprotein cholesterol, and glucose/insulin ratio (an insulin resistance index), with respect to patients with idiopathic hypersomnia without long sleep time (cerebrospinal fluid orexin-A levels > 300 pg/mL). Despite lower daily food intake, patients with narcolepsy with cataplexy displayed significant alterations in metabolic parameters resulting in a diagnosis of metabolic syndrome in more than half the cases.
CONCLUSIONS: BMI-independent metabolic alterations and the relative hypophagia of patients with narcolepsy with cataplexy, as compared with patients with idiopathic hypersomnia without long sleep time, suggest that orexin-A influences the etiology of this phenotype. Moreover, considering that these dysmetabolic alterations are present from a young age, a careful metabolic follow-up of patients diagnosed with narcolepsy with cataplexy is mandatory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19928388      PMCID: PMC2768955          DOI: 10.1093/sleep/32.11.1491

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  36 in total

1.  Increased body-mass index in patients with narcolepsy.

Authors:  A Schuld; J Hebebrand; F Geller; T Pollmächer
Journal:  Lancet       Date:  2000-04-08       Impact factor: 79.321

2.  A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms.

Authors:  J A Horne; O Ostberg
Journal:  Int J Chronobiol       Date:  1976

3.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

4.  Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness.

Authors:  M A Carskadon; W C Dement; M M Mitler; T Roth; P R Westbrook; S Keenan
Journal:  Sleep       Date:  1986-12       Impact factor: 5.849

5.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

6.  Orexin A activates locus coeruleus cell firing and increases arousal in the rat.

Authors:  J J Hagan; R A Leslie; S Patel; M L Evans; T A Wattam; S Holmes; C D Benham; S G Taylor; C Routledge; P Hemmati; R P Munton; T E Ashmeade; A S Shah; J P Hatcher; P D Hatcher; D N Jones; M I Smith; D C Piper; A J Hunter; R A Porter; N Upton
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 7.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness.

Authors:  J T Willie; R M Chemelli; C M Sinton; M Yanagisawa
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

8.  Peripheral leptin levels in narcoleptic patients.

Authors:  Norbert Dahmen; Alice Engel; Jana Helfrich; Nina Manderscheid; Mirjam Löbig; Thomas Forst; Andreas Pfützner; Peter Tonn
Journal:  Diabetes Technol Ther       Date:  2007-08       Impact factor: 6.118

9.  Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin.

Authors:  A N van den Pol; X B Gao; K Obrietan; T S Kilduff; A B Belousov
Journal:  J Neurosci       Date:  1998-10-01       Impact factor: 6.167

10.  Health-related quality of life among drug-naïve patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time.

Authors:  Akiko Ozaki; Yuichi Inoue; Toru Nakajima; Kenichi Hayashida; Makoto Honda; Yoko Komada; Kiyohisa Takahashi
Journal:  J Clin Sleep Med       Date:  2008-12-15       Impact factor: 4.062

View more
  35 in total

Review 1.  Sleep and obesity: a focus on animal models.

Authors:  Vijayakumar Mavanji; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Neurosci Biobehav Rev       Date:  2012-01-16       Impact factor: 8.989

2.  Autonomic response to periodic leg movements during sleep in narcolepsy-cataplexy.

Authors:  Yves Dauvilliers; Marie-Hélène Pennestri; Shirley Whittom; Paola A Lanfranchi; Jacques Y Montplaisir
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

3.  Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice.

Authors:  Stefano Bastianini; Alessandro Silvani; Chiara Berteotti; Jean-Luc Elghozi; Carlo Franzini; Pierluigi Lenzi; Viviana Lo Martire; Giovanna Zoccoli
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

Review 4.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

Review 5.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

6.  Orexin modulates brown adipose tissue thermogenesis.

Authors:  Christopher J Madden; Domenico Tupone; Shaun F Morrison
Journal:  Biomol Concepts       Date:  2012-08

7.  Glucose tolerance in patients with narcolepsy.

Authors:  Pierre A Beitinger; Stephany Fulda; Mira A Dalal; Renate Wehrle; Marietta Keckeis; Thomas C Wetter; Fang Han; Thomas Pollmächer; Andreas Schuld
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

Review 8.  Metabolic consequences of sleep and circadian disorders.

Authors:  Christopher M Depner; Ellen R Stothard; Kenneth P Wright
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

9.  Aberrant Food Choices after Satiation in Human Orexin-Deficient Narcolepsy Type 1.

Authors:  Ruth Janke van Holst; Lisa van der Cruijsen; Petra van Mierlo; Gert Jan Lammers; Roshan Cools; Sebastiaan Overeem; Esther Aarts
Journal:  Sleep       Date:  2016-11-01       Impact factor: 5.849

10.  High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy.

Authors:  Francesca Poli; Fabio Pizza; Emmanuel Mignot; Raffaele Ferri; Uberto Pagotto; Shahrad Taheri; Elena Finotti; Filippo Bernardi; Piero Pirazzoli; Alessandro Cicognani; Antonio Balsamo; Lino Nobili; Oliviero Bruni; Giuseppe Plazzi
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.